SEATTLE, April 07, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines ...

Atrasentan demonstrated mean proteinuria reductions of 38.1% proteinuria at six weeks of treatment, 48.3% at 12 weeks of treatment and 54.7% at 24 weeks of treatment There were no meaningful changes ...

In a recent study published in PLoS ONE, researchers assessed the binding of Galanthus nivalis agglutinin to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Study: Removal of ...

A team of scientists from China has recently deciphered the structural basis of comparatively higher binding affinity of two Omicron sub-variants, namely B.1.1 and B.2, for human ...